First clinical study started and long-term financing secured

Significant events during the second quarter 2021

  • Applied Ventures invested a further USD 0.5 million through the exercise of warrants issued in connection with the directed share issue in Q1 2021. Nanexa received SEK 4.3 million through the issue and the number of shares and votes in the company increased by 480,879 to 25,347,813 shares and votes.
  • Nanexa started its first clinical trial at the end of April 2021. It is a phase I study in the NEX-18 project to study pharmacokinetics, safety and tolerability. The first patients were treated at the end of May 2021.
  • Nanexa received approval in China in May 2021 for its basic patent, which covers the manufacturing method, products derived from it, and the use of PharmaShell®-coated drugs.
  • At Nanexa’s Annual General Meeting on May 24, it was decided, among other things, to elect Eva Nilsagård and Birgit Stattin Norinder as new Board members, on authorizations for the Board to decide on rights issue and directed issue, and to establish a warrant based incentive program for employees. A total of 380,000 warrants were thereafter subscribed for, corresponding to a maximum dilution of 1.5%.
  • In May 2021, Nanexa filed a complaint of patent infringement in the United States District Court of Delaware filed a patent infringement lawsuit against Vitrivax, Inc.
  • Nanexa decided in June 2021 to carry out a fully guaranteed rights issue of approximately SEK 127 million. The subscription period ran from 17 June to 1 July 2021.
  • Nanexa received approval in South Korea in June 2021 for its basic patent on PharmaShell®-coated drugs.

Significant events after the end of the period

  • The European Patent Office (EPO) communicated its intention to grant a European patent for Nanexa's PharmaShell® technology.
  • The rights issue of SEK 127 million decided in June was completed and registered in July 2021.

Summary of the reporting period 1 April - 30 June 2021

  • Turnover amounted to: TSEK 342 (97)
  • Operating profit (EBIT) amounted to: TSEK -8,296 (-6,430)
  • Profit after tax amounted to: TSEK -8,339 (-6,494)
  • Earnings per share amounted to: SEK -0.33 (-0.31)
  • Cash flow for the period amounted to: TSEK -6,253 (-9,961)
  • Cash and cash equivalents at end of period: TSEK 28,596 (34,089)

Summary of the reporting period 1 January - 30 June 2021

  • Turnover amounted to: TSEK 878 (1,289)
  • Operating profit (EBIT) amounted to: TSEK -14,919 (-9,899)
  • Profit after tax amounted to: TSEK -15,008 (-10,020)
  • Earnings per share amounted to: SEK -0.64 (-0.54)
  • Cash flow for the period amounted to: TSEK 15,905 (22,711)
  • Cash and cash equivalents at end of period: TSEK 28,596 (34,089)

         Figures in brackets refer to the corresponding period in the previous year.
  

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

This information is information that Nanexa is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-08-20 08:00 CEST.

Attachments

Nanexa Interim Report Jan Jun 2021

© Modular Finance, source Nordic Press Releases